Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inpatient Proposed Rule Maps Higher Payment Rates For Complex Stenting

This article was originally published in The Pink Sheet Daily

Executive Summary

Coronary stent diagnosis-related groups with secondary diagnoses would receive higher payments under the fiscal year 2006 inpatient prospective payment system proposed rule, the Centers for Medicare & Medicaid Services announces.

You may also be interested in...



Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled

The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.

GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG

HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.

CAP Median Bid Prices, Physician Indifference Likely Contributed To Vendors Spurning Contracts

BioScrip will be the only provider of Medicare Part B-covered drugs through the competitive acquisition program for three years.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel